@andybiotech don't expect $ will push victozza  on #nash but will prefer strategically oral semaglutide $emis regarding recent data in t2d. ozempic (injectable form) is currently studied in ph2 #nash and i expect $ will initiate poc study for oralsema $emis soon.
https://t.co/duhaqdzvcm